Barclays PLC Raises Holdings in LifeMD, Inc. (NASDAQ:LFMD)

Barclays PLC boosted its stake in shares of LifeMD, Inc. (NASDAQ:LFMD) by 311.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 49,017 shares of the company’s stock after purchasing an additional 37,112 shares during the quarter. Barclays PLC’s holdings in LifeMD were worth $257,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LFMD. Quest Partners LLC acquired a new position in shares of LifeMD in the 2nd quarter valued at $31,000. nVerses Capital LLC acquired a new position in shares of LifeMD in the 3rd quarter valued at $46,000. Intech Investment Management LLC acquired a new position in shares of LifeMD in the 3rd quarter valued at $54,000. CWM LLC acquired a new position in shares of LifeMD in the 3rd quarter valued at $59,000. Finally, SG Americas Securities LLC acquired a new position in shares of LifeMD in the 3rd quarter valued at $70,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

Insider Activity

In other news, CEO Justin Schreiber sold 25,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.52, for a total value of $163,000.00. Following the transaction, the chief executive officer now owns 2,728,715 shares in the company, valued at approximately $17,791,221.80. This represents a 0.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 15.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on LFMD shares. Mizuho started coverage on LifeMD in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of LifeMD in a report on Monday, November 11th. Lake Street Capital started coverage on LifeMD in a report on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 price objective on shares of LifeMD in a report on Friday, September 20th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.57.

LifeMD Price Performance

Shares of NASDAQ LFMD opened at $5.75 on Monday. The stock’s 50-day moving average is $5.50 and its two-hundred day moving average is $5.58. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78. LifeMD, Inc. has a 1-year low of $3.99 and a 1-year high of $12.88. The company has a market cap of $249.04 million, a price-to-earnings ratio of -8.98 and a beta of 1.38.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.